Description
Sitagliptin is an anti-diabetic/anti-hyperglycemic compound that inhibits dipeptidyl peptidase 4 (DPP4); sitagliptin also exhibits antioxidative and cardioprotective benefit. Sitagliptin decreases release of lactate dehydrogenase, malondialdehyde, and creatine kinase MB, and increases levels of glutathione peroxidase, glucagon-like peptide 1 (GLP-1), and superoxide dismutase; this compound also decreases expression of caspases 3 and 9, causing decreases in cardiac apoptosis and improvements in cardiac function. In hypertensive rats, sitagliptin increases levels of GLP-1, the GLP-1 receptor, cAMP, and eNOS and also increases activation of AMPK, improving vascular endothelial function.